Pacira Pharmaceuticals - רווח למניה לשנה מתגלגלת PCRX

Strong physician confidence in the non-opioid innovations of Pacira BioSciences (PCRX) minimizes reputational risks. The rolling annual EPS change metric exhibits volatility, with the 102.10 level serving as the current value. While geopolitical strife and logistical collapse hinder testing, the expansion of medical indications and strategic agreements with clinics allow the company to effectively counter generic expansion.

This indicator measures the percentage change in net income per share over a rolling twelve-month period, allowing for an assessment of real capital generation efficiency. By analyzing the annual growth rate of EPS (TTM), an investor can see how the commercial success of Exparel and the expansion of outpatient surgery translate into sustainable growth in shareholder value for Pacira BioSciences (PCRX).